-
Modern Rheumatology Jan 2017Multicentric reticulohistiocytosis (MRH) is a rare non-Langerhans histiocytosis of unknown etiology with a predilection for joint and skin. The characteristic clinical...
Multicentric reticulohistiocytosis (MRH) is a rare non-Langerhans histiocytosis of unknown etiology with a predilection for joint and skin. The characteristic clinical features are papulonodular skin eruptions and inflammatory polyarthritis, sometimes progressive to arthritis mutilans, a severe destructive arthropathy. Although these manifestations can present at the same time, it is more common that one feature precedes the others. Notably, these features are similar to those found in some rheumatic diseases, such as rheumatoid arthritis or dermatomyositis, and this can lead to a misdiagnosis, especially during periods where only one feature is present. Herein, we report a female patient with polyarthralgia and subsequent skin eruptions, who was eventually diagnosed with MRH. Her symptoms seemed to resemble those of some rheumatic diseases, but several features such as affected joints and the characteristic shape of the skin lesions did not correspond to that. The histological result of infiltration of histiocytes and multinucleated giant cells in the skin ultimately facilitated the correct diagnosis. In this paper, we review MRH briefly and highlight several differential points which enable us to increase the likelihood of correctly diagnosing MRH.
Topics: Arthralgia; Arthritis; Diagnosis, Differential; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Middle Aged; Skin; Skin Diseases
PubMed: 25211404
DOI: 10.3109/14397595.2014.952702 -
Immunity, Inflammation and Disease Oct 2023Since the coronavirus outbreak became a global health emergency in 2020, various immune-based effects, such as inflammatory arthritis (IA), have been recorded. This... (Review)
Review
AIM
Since the coronavirus outbreak became a global health emergency in 2020, various immune-based effects, such as inflammatory arthritis (IA), have been recorded. This study aimed to determine the role of COVID-19 severity on post-COVID arthritis.
METHODS
We systematically reviewed 95 patients who developed arthritis after severe and non-severe COVID-19 infection by searching the databases, including PubMed, SCOPUS, and EMBASE. We used the term "COVID-associated arthritis" because there was no definite diagnostic method for classifying arthritides after COVID-19 infection, and the diagnosed arthritis types were based on the authors' viewpoints.
RESULTS
After evaluating the data between the two severe and non-severe COVID-19-infected groups of patients, the results showed that the COVID-19 severity may affect the pattern of joint involvement in IA. In both groups, combination therapy, including oral nonsteroidal anti-inflammatory drugs with different types of corticosteroids, was the most common treatment. In addition, the mean age and comorbidities rate was higher in the severe COVID-19 group. Even though the patients in the severe COVID-19 group developed more serious COVID-19 symptoms, they experienced milder arthritis with better outcomes and more delayed onsets that required less aggressive therapy.
CONCLUSION
We conclude that there may be an inverse relationship between COVID-19 severity and arthritis severity, possibly due to weaker immunity conditions following immunosuppressant treatments in patients with severe COVID-19.
Topics: Humans; COVID-19; Arthritis; Immunosuppressive Agents
PubMed: 37904701
DOI: 10.1002/iid3.1035 -
Rheumatology (Oxford, England) Feb 2016There is now a general consensus that RA has a spectrum of disease stages that can begin many years before the onset of clinical symptoms. It is widely thought that... (Review)
Review
There is now a general consensus that RA has a spectrum of disease stages that can begin many years before the onset of clinical symptoms. It is widely thought that understanding the complex interplay between genetics and environment, and their role in pathogenesis, is essential in gaining further insight into the mechanisms that drive disease development and progression. More than 100 genetic susceptibility loci have now been identified for RA through studies that have focused on patients with established RA compared with healthy controls. Studying the early preclinical phases of disease will provide valuable insights into the biological events that precede disease and could potentially identify biomarkers to predict disease onset and future therapeutic targets. In this review we will cover recent advances in the knowledge of genetic and environmental risk factors and speculate on how these factors may influence the transition from one stage of disease to another.
Topics: Arthritis, Rheumatoid; Autoimmunity; Disease Progression; Genetic Predisposition to Disease; Humans; Prognosis; Risk Factors
PubMed: 25239882
DOI: 10.1093/rheumatology/keu323 -
Acta Ophthalmologica Jun 2023The purpose of this perspective was to shed light on screening of uveitis among Nordic children with juvenile idiopathic arthritis (JIA).
PURPOSE
The purpose of this perspective was to shed light on screening of uveitis among Nordic children with juvenile idiopathic arthritis (JIA).
METHODS
A literature search was conducted to review predictors of JIA-uveitis and previous JIA-uveitis screening recommendations.
RESULTS
Predictors of uveitis in JIA are younger age and positive antinuclear antibody titre at onset of JIA, specific subtypes of JIA (extended and persistent oligoarthritis, rheumatoid factor negative polyarthritis and psoriatic arthritis) and short duration of JIA. Methotrexate and monoclonal tumour necrosis factor (TNF) inhibitor treatment reduce the risk JIA-uveitis.
CONCLUSION
Children with all of the above risk factors should be screened frequently but if they receive TNF inhibitor or methotrexate therapy, they may be screened less frequently. Children with none of the risk factors do not benefit from long-term screening for uveitis. A guideline for intervals and overall length of screening was prepared considering currently known risk factors for JIA-uveitis, the Nordic population and previous guidelines.
Topics: Child; Humans; Arthritis, Juvenile; Methotrexate; Uveitis; Risk Factors; Time Factors
PubMed: 36458735
DOI: 10.1111/aos.15299 -
BMJ Case Reports Mar 2022Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by symmetric inflammatory polyarthritis. However, RA limited to a single joint is extremely rare....
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by symmetric inflammatory polyarthritis. However, RA limited to a single joint is extremely rare. Here, we report a middle-aged woman who presented with insidious right elbow arthritis. She had no other peripheral joint pain, tenderness or swelling. She had high-positive anti-cyclic citrullinated peptide antibodies. An MRI of the right elbow showed capsular distension, joint effusion and bone marrow oedema. Synovial biopsy revealed hyperplasia with lymphoplasmacytic infiltrate consistent with RA. Therapy with methotrexate 7.5 mg orally weekly was effective to control her inflammatory arthritis. This case highlights the relevance of synovial tissue analysis for patients presenting with chronic inflammatory monarthritis when the cause is not clinically evident, and the importance of considering RA even in the absence of polyarticular involvement. Delayed diagnosis and treatment of inflammatory monarthritis can lead to joint destruction and disability.
Topics: Arthritis, Rheumatoid; Autoantibodies; Elbow; Elbow Joint; Female; Humans; Middle Aged; Synovial Membrane
PubMed: 35256364
DOI: 10.1136/bcr-2021-246863 -
Enfermedades Infecciosas Y... Feb 2023
Topics: Humans; Arthritis, Rheumatoid
PubMed: 36280581
DOI: 10.1016/j.eimce.2022.10.007 -
Journal Der Deutschen Dermatologischen... May 2019
Review
Topics: Arthritis; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pancreatitis; Panniculitis; Syndrome
PubMed: 30994265
DOI: 10.1111/ddg.13839 -
Lancet (London, England) Mar 2017
Topics: Arthritis; Disease Management; Humans; United States
PubMed: 28322804
DOI: 10.1016/S0140-6736(17)30765-1 -
Seminars in Arthritis and Rheumatism Feb 2018The Crafoord Prize in Polyarthritis ranks as one of the most prestigious prizes and can be awarded only if the Royal Swedish Academy of Sciences decides the likelihood... (Review)
Review
The Crafoord Prize in Polyarthritis ranks as one of the most prestigious prizes and can be awarded only if the Royal Swedish Academy of Sciences decides the likelihood of prize worthy progress in the field, and at most every 4th year. This has happened only four times since 1982. This year the 5th Laureates were Shimon Sakaguchi, Fred Ramsdell, and Alexander Rudensky with the motivation "for their discoveries relating to regulatory T cells, which counteract harmful immune reactions in arthritis and other autoimmune diseases". Here I review the history of their contributions and its impact in rheumatology.
Topics: Arthritis; Autoimmune Diseases; Awards and Prizes; Humans; Rheumatology; T-Lymphocytes, Regulatory
PubMed: 29037524
DOI: 10.1016/j.semarthrit.2017.08.010 -
Revue Medicale Suisse Jan 2017
Topics: Arthritis; Finger Joint; Humans; Practice Guidelines as Topic
PubMed: 28703988
DOI: No ID Found